The Supply of Medical Radioisotopes [electronic resource]: Market Impacts of Converting to Low-enriched Uranium Targets for Medical Isotope Production /
Organisation for Economic Co-operation and Development.
Organisation for Economic Co-operation and DevelopmentContributor
Organisation for Economic Co-operation and DevelopmentContent Provider
Paris : OECD Publishing,
2012.
The reliable supply of molybdenum-99 (99Mo) and its decay product, technetium-99m (99mTc), is a vital component of modern medical diagnostic practices. At present, most of the global production of 99Mo is from highly enriched uranium (HEU) targets. However, all major 99Mo-producing countries have recently agreed to convernt to using low-enriched uranium targetts for the production of 99Mo. This report describes the market impact of this conversion both in terms of costs, available capacity as well as the policy actions that are needed.  
Executive Summary 7 Introduction 15 -Purpose of the study 15 -HEU use in the supply chain 16 -Overiew of the NEA study on LEU-target conversion impacts 16 -Sources and uncertainties around information 18 2. Capacity impacts of LE-target conversion 19 -Framework and methodology of capacity modelling 19 -Reference capacity data 22 -Economic- and technology-challenges situations 26 -Capacity impact elements 26 -Capacity impacts from converting to LEU targets 29 -Comment on high-density targets 35 -Conclusions regarding the expected capacity impacts from LEU-target conversion 36 3. Cost impacts of LEU-target conversion 37 -Framework and methodology of economic modelling 37 -Economic modelling scenarios 39 -Cost impact elements 39 -Cost impacts from converting to LEU targets 44 -Conclusions regarding the expected cost impacts from LEU-target conversion 50 4. Conclusions on the market impacts of converting to the use of LEU targets for 39Mo production 51 References 52 Annexes -1. Expert working group 53 -2. Capacity impact elements 57 -3 Cost impact elements 61
The reliable supply of molybdenum-99 (99Mo) and its decay product, technetium-99m (99mTc), is a vital component of modern medical diagnostic practices. At present, most of the global production of 99Mo is from highly enriched uranium (HEU) targets. However, all major 99Mo-producing countries have recently agreed to convernt to using low-enriched uranium targetts for the production of 99Mo. This report describes the market impact of this conversion both in terms of costs, available capacity as well as the policy actions that are needed.  
Bibliographic Level Mode of Issuance: Monograph
Nuclear Energy
Physics
Physical Sciences & Mathematics
Nuclear Physics